Marxsa schreef op 20 juni 2020 08:53:
[...]
Researchers now compared the cost-effectiveness of these four on-demand HAE therapies in a study
funded by Pharming Healthcare, the manufacturer of Ruconest.
Overall, the models suggested Ruconest as the most cost-effective of the four treatments analyzed, at an estimated $12,905 per attack. This was followed by Berinert ($14,668 per attack), Firazyr ($14,806 per attack), and Kalbitor ($21,068 per attack).
Goed gevonden!